{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=24", "query": { "intervention": "lenalidomide", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 703, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T16:55:47.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00619684", "title": "Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-02", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-05-18", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619684" }, { "nct_id": "NCT02336815", "title": "Selinexor Treatment of Refractory Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2015-05-26", "completion_date": "2019-07-26", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02336815" }, { "nct_id": "NCT02954406", "title": "A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-03-05", "completion_date": "2020-07-27", "has_results": true, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 11, "location_summary": "Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954406" }, { "nct_id": "NCT02188368", "title": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "POM", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "CFZ", "type": "DRUG" }, { "name": "BTZ", "type": "DRUG" }, { "name": "CLA", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-07-07", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 12, "location_summary": "Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188368" }, { "nct_id": "NCT04396496", "title": "Treatment of POEMS Syndrome With Daratumumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "POEMS Syndrome" ], "interventions": [ { "name": "Daratumumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-09-22", "completion_date": "2023-10-16", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396496" }, { "nct_id": "NCT00790842", "title": "Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Anticoagulants", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2009-01-21", "completion_date": "2018-03-08", "has_results": true, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ames", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790842" }, { "nct_id": "NCT04174196", "title": "A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasmacytoma", "Plasmacytoma of Bone", "Multiple Myeloma" ], "interventions": [ { "name": "CC-486", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-11-19", "completion_date": "2026-11-19", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04174196" }, { "nct_id": "NCT01379274", "title": "A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MDS" ], "interventions": [ { "name": "Lenalidomide and azacitidine combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379274" }, { "nct_id": "NCT01005979", "title": "A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Lenalidomide, Rituximab, and Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-08-13", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005979" }, { "nct_id": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-05-27", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-25T16:55:47.851Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995669" } ] }